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Abstract:  Blood  pressure  (BP)  is  regulated  by  multiple  neuronal,  hormonal,  renal  and 
vascular  control  mechanisms.  Changes  in  signaling  mechanisms  in  the  endothelium, 
vascular smooth muscle (VSM) and extracellular matrix cause alterations in vascular tone 
and blood vessel remodeling and may lead to persistent increases in vascular resistance and 
hypertension (HTN). In VSM, activation of surface receptors by vasoconstrictor stimuli 
causes an increase in intracellular free Ca
2+ concentration ([Ca
2+]i), which forms a complex 
with  calmodulin,  activates  myosin  light  chain  (MLC)  kinase  and  leads  to  MLC 
phosphorylation, actin-myosin interaction and VSM contraction. Vasoconstrictor agonists 
could  also  increase  the  production  of  diacylglycerol  which  activates  protein  kinase  C 
(PKC).  PKC  is  a  family  of  Ca
2+-dependent  and  Ca
2+-independent  isozymes  that  have 
different distributions in various blood vessels, and undergo translocation from the cytosol 
to the plasma membrane, cytoskeleton or the nucleus during cell activation. In VSM, PKC 
translocation to the cell surface may trigger a cascade of biochemical events leading to 
activation  of  mitogen-activated  protein  kinase  (MAPK)  and  MAPK  kinase  (MEK),  a 
pathway  that  ultimately  increases  the  myofilament  force  sensitivity  to  [Ca
2+]i,  and 
enhances actin-myosin interaction and VSM contraction. PKC translocation to the nucleus 
may induce transactivation of various genes and promote VSM growth and proliferation. 
PKC  could  also  affect  endothelium-derived  relaxing  and  contracting  factors  as  well  as 
matrix  metalloproteinases (MMPs)  in the extracellular  matrix  further affecting vascular 
reactivity  and  remodeling.  In  addition  to  vasoactive  factors,  reactive  oxygen  species, 
inflammatory cytokines and other metabolic factors could affect PKC activity. Increased 
PKC expression and activity have been observed in vascular disease and in certain forms 
of experimental and human HTN. Targeting of vascular PKC using PKC inhibitors may 
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function in concert with antioxidants, MMP inhibitors and cytokine antagonists to reduce 
VSM hyperactivity in certain forms of HTN that do not respond to Ca
2+ channel blockers. 
Keywords: calcium; endothelium; vascular smooth muscle; hypertension 
 
List  of  abbreviations:  ANG  II:  angiotensin  II;  ATP:  adenosine  triphosphate;  
BP:  blood  pressure;  CPI-17:  PKC-potentiated  phosphatase  inhibitor  protein-17  kDa;  
CAM:  calmodulin;  DAG:  diacylglycerol;  EC:  endothelial  cell;  ET-1:  endothelin-1;  
HTN:  hypertension;  IP3:  inositol  1,4,5-trisphosphate;  MAPK:  mitogen-activated  protein 
kinase;  MARCKs:  myristoylated  alanine-rich  C-kinase  substrate;  MMP:  matrix 
metalloproteinase; MEK: MAPK kinase; MLC: myosin light chain; NADPH: nicotinamide 
adenine  dinucleotide  phosphate;  O2
−•:  superoxide;  PDBu:  phorbol  12,13-dibutyrate;  
PIP2: phosphatidylinositol 4,5-bisphosphate; PLC: phospholipase C; PKC: protein kinase C; 
PMA:  phorbol  myristate  acetate;  RACKs:  receptors  for  activated  C-kinase;  
RAS: renin-angiotensin system;  Rho-kinase: Rho-associated kinase;  ROS: reactive oxygen 
species;  SHR:  spontaneously  hypertensive  rat;  TPA:  12-o-tetradecanoylphorbol-13-acetate; 
VSMC: vascular smooth muscle cell; WKY: Wistar-Kyoto 
1. Introduction 
Hypertension (HTN) is a major cardiovascular and renal disease affecting a large proportion of the 
population in the Western World. Several factors contribute to increased blood pressure (BP) including 
neuronal, hormonal, renal and vascular mechanisms. Understanding the physiological mechanisms that 
control BP would help define the pathological changes in HTN, and help design specific approaches to 
manage the increases in BP and HTN. 
Blood vessels play a major role in the control of vascular tone. The blood vessel wall has three 
layers; the tunica intima made of a single layer of endothelial cells (ECs), the tunica media made of 
several  layers  of  vascular  smooth  muscle  cells  (VSMCs),  and  the  adventitia  made  of  fibroblasts, 
connective  tissue  and  extracellular  matrix  (ECM).  ECs  release  vasodilator  and  vasoconstrictor 
mediators  that  control  the  vessel  diameter.  The  ability  of  VSMCs  to  contract  and  relax  plays  an 
important role in the regulation of the vessel diameter and blood flow to various tissues and organs. 
The  ECM  proteins  provide  structural  integrity  to the  vessel  wall  and  are  regulated  by  proteolytic 
enzymes such as matrix metalloproteinases (MMPs). 
This review will focus on how vasoconstrictor agonists affect the mechanisms of VSM contraction 
particularly protein kinase C (PKC), and the changes in these mechanisms in vascular disease such as 
HTN. The role of PKC in the regulation of EC function and ECM will be briefly discussed. In addition 
to  changes  in  vasoactive  factors,  changes  in  reactive  oxygen  species  (ROS)  [1–3],  MMPs  and 
inflammatory cytokines [4–6] in the plasma and vascular tissues [7–9] have been observed in HTN and 
coronary artery disease. The effects of ROS [2,3], MMPs [10–12] and cytokines [13–15] in HTN may 
be partly related to their effects on PKC and consequent changes in vascular reactivity, growth and 
remodeling. Understanding the role of PKC as a major regulator of VSM function, the PKC isoforms, Pharmaceuticals 2013, 6  409 
 
 
their protein substrates and subcellular distribution, and their interaction with other factors such as 
ROS, MMPs and cytokines would provide important information regarding the benefits of determining 
PKC activity in the diagnosis of VSM hyperactivity disorders and the potential usefulness of PKC 
inhibitors in the management of vascular disease such as HTN. 
2. Mechanisms of VSM Contraction 
Ca
2+  is  a  major  determinant  of  VSM  contraction.  VSM  activation  by  physiological  or 
pharmacological agonist triggers an increase in intracellular free Ca
2+ concentration ([Ca
2+]i) due to 
Ca
2+ release from the sarcoplasmic reticulum and Ca
2+ influx from the extracellular space through 
plasma  membrane  Ca
2+  channels.  Four  Ca
2+  ions  bind to calmodulin (CAM) to  form  a  Ca
2+-CAM 
complex, which activates myosin light chain (MLC) kinase, and in turn causes the phosphorylation of 
the 20 kDa MLC, stimulates actin-myosin interaction and promotes VSM contraction (Figure 1). During 
VSM  relaxation,  removal  of  the  vasoconstrictive  agonist  causes  a  decrease  in  [Ca
2+]i  due  to  Ca
2+ 
extrusion  via  the  plasmalemmal  Ca
2+  pump  (PMCA)  and  the  Na
+-Ca
2+  exchanger,  as  well  as  Ca
2+ 
reuptake  via  the  sarcoplasmic  reticulum  Ca
2+  pump  (SERCA).  The  decrease  in  [Ca
2+]i  allows  the 
dissociation of the Ca
2+-CAM complex, and the remaining phosphorylated MLC is dephosphorylated by 
MLC phosphatase, leading to detachment of actin-myosin crossbridges and VSM relaxation [16–19]. 
Ca
2+-dependent  VSM  contraction  is  usually  observed  during  VSM  depolarization  by  mechanical 
stretch,  nerve  stimuli,  electrical  stimulation,  or  in  the  presence  of  high  KCl  solution.  VSM 
depolarization activates voltage-gated Ca
2+ channels (VGCCs) and because of the large concentration 
gradient between extracellular Ca
2+ (millimolar) and intracellular [Ca
2+]i (nanomolar), the opening of 
VGCCs facilitates Ca
2+ influx, and leads to MLC phosphorylation and VSM contraction. In contrast 
with membrane depolarization, physiological agonists such as norepinephrine, prostaglandin F2 and 
thromboxane A2 activate other intracellular signaling pathways in addition to Ca
2+ channels. In VSM, 
the interaction of an agonist with its specific receptor causes activation of phospholipase C (PLC), and 
promotes the hydrolysis of phosphatidylinositol 4,5-bisphosphate into inositol 1,4,5-trisphosphate (IP3) 
and diacylglycerol (DAG) [20,21]. Because IP3 is water soluble it diffuses in the cytosol, stimulates 
IP3  receptors  in  the  sarcoplasmic  reticulum  and  causes  Ca
2+  release  from  the  intracellular  stores, 
transient increase in [Ca
2+]i and VSM contraction. Agonists also activate receptor-operated (ROCs) 
and store-operated Ca
2+ channels (SOCs), causing  maintained Ca
2+  influx,  increased [Ca
2+]i, MLC 
phosphorylation and VSM contraction (Figure 1). However, Ca
2+-dependent MLC phosphorylation may 
not be the only mechanism involved in VSM contraction. For instance, Ca
2+ channel blockers such as 
nifedipine, verapamil or diltiazem do not completely inhibit agonist-induced VSM contraction. Also, 
agonist-induced maintained contraction has been observed in certain blood vessels incubated in Ca
2+-free 
solution and in the absence of detectable increases in [Ca
2+]i [17,22–24]. Agonist-induced dissociations 
between [Ca
2+]i and force, between [Ca
2+]i and MLC phosphorylation, and between MLC phosphorylation 
and  force  have  also  been  observed  in  several  vascular  preparations,  suggesting  activation  of  
additional signaling pathways that cause sensitization of the contractile myofilaments to [Ca
2+]i including  
Rho-kinase and protein kinase C (PKC) [16,18]. Pharmaceuticals 2013, 6  410 
 
 
Figure  1.  Mechanisms  of  VSM  contraction.  The  interaction  of  an  agonist  (A)  such  as 
phenylephrine  with  its  specific  -adrenergic  receptor  (R)  activates  phospholipase  C 
(PLCβ) and stimulates the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into 
inositol-1,4,5-trisphosphate  (IP3)  and  diacylglycerol  (DAG).  IP3  stimulates  Ca
2+  release 
from the sarcoplasmic reticulum (SR). Agonists also stimulate Ca
2+ influx through Ca
2+ 
channels.  Ca
2+  binds  calmodulin  (CAM),  activates  MLC  kinase  (MLCK),  causes  MLC 
phosphorylation,  and  initiates  VSM  contraction.  DAG  activates  PKC.  PKC-induced 
phosphorylation of CPI-17, inhibits MLC phosphatase and increases MLC phosphorylation 
and VSM contraction. PKC-induced phosphorylation of the actin-binding protein calponin 
(CaP) allows more actin to bind myosin and enhances contraction. PKC may also activate a 
protein  kinase  cascade  involving  Raf,  MAPK  kinase  (MEK)  and  MAPK,  leading  to 
phosphorylation of the actin-binding protein caldesmon (CaD) and enhanced contraction. 
Activation of RhoA/Rho-kinase inhibits MLC phosphatase and further enhances the Ca
2+ 
sensitivity of contractile proteins. AA, arachidonic acid; G, heterotrimeric GTP-binding 
protein; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PLD, phopholipase D; 
PS, phosphatidylserine. Dashed line indicates inhibition. 
 
3. PKC Isoforms 
PKC  was  first  described  as  a  Ca
2+-activated  phospholipid-dependent  protein  kinase  [25],  but 
subsequent biochemical analysis and molecular cloning revealed a family of different PKC isozymes 
of  closely  related  structure.  The  PKC  molecule  is  a  single  polypeptide,  comprised  of  N-terminal 
regulatory  domain  and  C-terminal  catalytic  domain  (Figure  2)  separated  by  a  hinge  region  that 
becomes proteolytically labile when the enzyme is membrane-bound [26]. Classic PKCs have four Pharmaceuticals 2013, 6  411 
 
 
conserved  regions  (C1–C4)  and  five  variable  regions  (V1–V5).  The  C1  region  contains  a tandem 
repeat  of  the  characteristic  cysteine-rich  zinc-finger-like  sequence.  The  sequence  Cys-X2-Cys-
X13(14)-Cys-X7-Cys-X7-Cys,  where  X  represents  any  amino  acid,  is  conserved  among  different 
PKCs, and each 30-residue sequence of this type is independently folded and binds a zinc ion [27]. 
The Cys-rich motif is duplicated in most PKCs and may form the DAG/phorbol ester-binding site. The 
Cys-rich motif is also immediately preceded by an autoinhibitory pseudosubstrate sequence. The C1 
region also contains the phosphatidylserine recognition site [26]. In Ca
2+-dependent PKCs, the C2 
region  is  rich  in  acidic  residues  and  has  a  Ca
2+-binding  site.  The  C3  and  C4  regions  contain  the 
adenosine triphosphate (ATP) and substrate binding sites. Similar to other protein kinases, all PKCs 
have an ATP-binding sequence, Gly-X-Gly-X-X-Gly-----Lys [21,26] (Figure 2). 
Figure 2. Biochemical structure of a classic PKC, and sites of action of activators and 
inhibitors. A classic PKC molecule has four conserved (C1–C4) and five variable (V1–V5) 
regions. C1 region contains binding sites for DAG, phorbol ester, and phosphatidylserine, 
and for the PKC inhibitor calphostin C. C2 region contains Ca
2+-binding site. C3 regions 
contain binding sites for ATP and the PKC inhibitors H-7 and staurosporine. C4 region 
contains binding sites for physiological PKC substrate. Endogenous pseudosubstrate and 
exogenous  pseudosubstrate  inhibitor  peptide  bind  to  the  catalytic  domain  and  prevents 
PKC from phosphorylating the true substrate. Upon activation, the PKC molecule unfolds 
to remove endogenous pseudosubstrate, and bring ATP into proximity with the substrate. 
 
PKC isoforms are generally classified into three subgroups, conventional or classic  cPKs, novel 
nPKCs, and atypical aPKCs (Table 1). cPKCs include , I, II, and  PKC. They have the traditional 
4 conserved regions (C1–C4) and the 5 variable regions (V1–V5). The cDNA clones for , I, II and 
 PKC were isolated from bovine [28,29], rat [30], rabbit [31] and human brain libraries [28]. I and 
II cDNAs are derived from a single mRNA transcript by alternative splicing, and differ only in ~50 
amino acid residues in their carboxyl-terminal end in the variable region V5 [30,31]. Because , I, 
II  and  -PKC  have  a  phorbol  ester  biding  site,  they  are  down-regulated  by  prolonged  exposure  
to  phorbol  esters.  nPKCs  include  ,  ,  (L)  and    PKC.  They  lack  the  C2  region  and  are  
Ca
2+-independent [30]. -PKC differs from -, I-, II-, and -PKC in that the V1 region is extended 
while the C2 region  is deleted [32]. -PKC shows the highest sequence similarity to -PKC with Pharmaceuticals 2013, 6  412 
 
 
59.4% identity [33]. PKC L, is the human homologue of mouse -PKC [34]. -PKC consists of 707 
amino acids and shows the highest sequence similarity to -PKC (67% identity) [33]. aPKCs include  
and  /  PKC,  and  characteristically  have  only  one  Cys-rich  zinc  finger-like  motif.  aPKCs  are 
dependent on phosphatidylserine, but are not affected by DAG, phorbol esters or Ca
2+, and therefore 
do not translocate or downregulate in response to phorbol esters or DAG [30] (Table 1). 
Table 1. Representative PKC Distribution and Subcellular Distribution in Blood Vessels. 
PKC 
MW 
(kDa) 
Blood Vessel  Resting Cell  Activated Cell  Ref 
Classic 
  74–82 
Rat aorta  Cytosolic  Nuclear  [35] 
Rat Carotid artery  Cytosolic  Membrane  [36] 
Rat mesenteric artery  Cytosolic/membrane  Cytosolic/Membrane  [37] 
Porcine coronary artery  Cytosolic  Membrane  [38] 
Bovine aorta  Cytosolic  Membrane  [39] 
Ferret portal vein  Cytosolic  Surface membrane  [40] 
  80–82 
Rat aorta  Cytosolic  Nuclear  [35] 
Rat Carotid artery  Cytosolic  Membrane  [36] 
  70–82  Rat mesenteric artery  Cytosolic  Cytosolic  [37] 
Novel 
  76–82 
Rat aorta  Cytoskeleton/organelle  Cytoskeleton/organelle  [41] 
Rat mesenteric artery  Membrane  Membrane  [37] 
  90–97 
Rat mesenteric artery  Cytosolic/membrane  Cytosolic/membrane  [37] 
Ferret aorta  Cytosol  Surface membrane  [42] 
Porcine coronary artery  Cytosolic  Membrane  [38] 
    NIH 3T3 fibroblasts  Cytosolic/membrane  Membrane  [43] 
Atypical 
  64–82 
Rat aorta  Perinuclear  Intranuclear  [41] 
Rat mesenteric artery  Cytosolic  Cytosolic  [37] 
Ferret aorta, portal vein  Perinuclear  Intranuclear  [42] 
/  70 
Rabbit femoral artery 
Cytosolic  Cytosolic  [44] 
Rabbit portal vein 
4. PKC Substrates 
The inactive PKC molecule is folded such that the basic autoinhibitory pseudosubstrate is tightly 
bound to the acidic patch in the substrate-binding site, a conformation that protects it from proteolysis. 
When PKC is activated by phosphatidylserine, DAG and Ca
2+ the pseudosubstrate becomes unmasked 
and liable to proteolysis. This is supported by the observation pseudosubstrate antibodies activate PKC 
likely by removing the pseudosubstrate from the active substrate binding site [45]. Activated PKC 
phosphorylates  arginine-rich  protein  substrates, and  these  peptides  neutralize  the  acidic  patch  that 
maintains the pseudosubstrate in the active site, thus displacing the basic pseudosubstrate from the Pharmaceuticals 2013, 6  413 
 
 
substrate-binding site in the catalytic domain [26,46,47]. The amino acid sequence in the vicinity of the 
substrate phosphorylation site may provide a substrate recognition guide for PKC and structure-function 
studies  of  synthetic  peptide  substrates  suggest  that  PKC  requires  basic  residue  determinants  in 
common with other serine/threonine protein kinases [47]. 
Common PKC substrates include lysine-rich histone and myelin basic protein [25]. -, -, -, and  
-PKC are potent histone IIIS kinases. -, -, and -PKC do not adequately phosphorylate histone IIIS, 
but readily phosphorylate myelin basic protein [32,48,49]. However, removal of the regulatory domain 
of -PKC by limited proteolysis generates a catalytic fragment that can phosphorylate histone IIIS [32]. 
Myristoylated, alanine-rich C kinase substrate (MARCKS) is an 87-kDa protein and a major PKC 
substrate that  binds  F-actin  and  bridges  cytoskeletal  actin  to the  plasma  membrane  [50,51].  Also,  
PKC-induced phosphorylation of the inhibitory GTP-binding protein Gi facilitates the dissociation of 
its i subunit from adenylyl cyclase and leads to increased adenylyl cyclase activity [52]. Other PKC 
substrates  include  plasma  membrane  ion  channels  and  pumps.  PKC  inhibits  Ca
2+-dependent  large 
conductance K
+ channel (BKCa) in pulmonary VSM [53]. Also, thromboxane A2 may inhibit voltage-gated 
K
+ channels and pulmonary vasoconstriction via a mechanism involving -PKC [54]. PKC-induced 
phosphorylation of SERCA promotes Ca
2+ uptake, and activation of PMCA promotes Ca
2+ extrusion, 
leading to reduction in agonist-induced increase in VSM [Ca
2+]i [55]. PKC may phosphorylate the 1 
subunit of Na
+/K
+-ATPase, and activate the Na
+/H
+ exchanger and thereby increase cytoplasmic pH 
and cause cell alkalinization [56,57]. 
PKC  substrates  also  include  cytoskeletal  and  regulatory  proteins  in  VSM.  PKC-induced 
phosphorylation  of  vinculin,  a  cytoskeletal  protein  localized  at  adhesion  plaques,  could  affect  cell 
shape and adhesion properties [58]. PKC also causes phosphorylation of the CPI-17 regulatory protein 
leading  to  inhibition  of  MLC  phosphatase,  increased  MLC  phosphorylation  and  enhanced  VSM 
contraction [59]. Also, -PKC phosphorylates the actin-binding protein calponin, allowing more actin 
to interact with myosin and further VSM contraction [29]. However, PKC could also phosphorylate the 
20-kDa MLC and MLC kinase, leading to inhibition of Ca
2+-dependent actin-myosin interaction and 
VSM contraction [60]. 
5. PKC Distribution 
PKC isoforms are expressed in various vascular beds (Table 1). -PKC is a universally expressed in 
almost all blood vessels examined. -PKC is expressed mainly in neurons and nerve endings of blood 
vessels. -PKC is mainly associated with the cytoskeleton. -PKC is universally expressed in many 
vascular tissues. /L-PKC is expressed in the lung, skin, heart and brain, -PKC in skeletal muscle and 
/-PKC in the testis and ovary [49]. 
In resting cells, ,  and -PKC are localized mainly in the cytosolic fraction, and activated PKC 
undergoes translocation from the cytosolic to the particulate and membrane fraction [61,62]. Activated 
-, - and -PKC usually undergo translocation from the cytosol to the cell membrane [63] (Table 1). 
However, in normal fibroblasts, -PKC is tightly associated with the cytoskeleton and organized into 
plasmalemmal focal contacts which are composed of structural proteins such as vinculin, talin, integrin 
and -actinin that allow the attachment of cytoskeletal microfilaments to the plasma membrane [64]. 
In neural cells, I-PKC is associated with the plasma membrane, while II-PKC is localized in the Pharmaceuticals 2013, 6  414 
 
 
Golgi complex [21]. In the cerebellum, -PKC is present in the cell bodies, dendrites and axons of 
Purkinje’s  cells.  Immuno-electron  microscopy  revealed  that  -PKC  is  associated  with  most  cell 
membranous structures, except the nucleus [65]. 
Because -PKC is localized in the vicinity of the cytoskeleton, it is often identified in the particulate 
fraction  of  both  resting  and  activated  cells.  In  contrast,  -PKC  undergoes  translocation  from  the 
cytosol to the surface membrane during VSM activation.  -PKC is localized in the vicinity of the 
nucleus in both resting and activated mature VSMCs [42]. However, in the developing embryo, -PKC may 
have different distribution and function and may play a role in perinatal pulmonary vasoconstriction [66]. 
Different  physico-chemical  forces  may  drive  PKC  translocation  including  simple  diffusion  or 
specific targeting mechanisms that allow tight binding of PKC to its target substrate. Some of the 
targeting mechanisms include conformation changes and altered hydrophobicity,  lipid modification, 
phosphorylation and targeting sequences. For instance, binding of Ca
2+ or DAG to PKC may cause 
conformational changes that unfolds the PKC molecule and result in exposure of the substrate region 
and increased PKC hydrophobicity and binding to membrane lipids [26]. Also, modification in the 
lipid component of a protein could influence its subcellular distribution. The VSM plasma membrane 
is composed of several domains of focal adhesions alternating with zones rich in caveolae, and both 
harbor a subset of membrane-associated proteins. Also, the plasma membrane lipids are segregated 
into cholesterol-rich lipid rafts and glycerophospholipid-rich non-raft regions, an arrangement that is 
critical for preserving the membrane protein architecture and for the translocation of proteins to the 
plasma  membrane.  In  VSMC  membrane,  lipid  segregation  is  supported  by  annexins  that  target 
membrane  sites  of  distinct  lipid  composition,  and  each  annexin  requires  different  [Ca
2+]  for  its 
translocation to the plasma membrane, thus allowing a spatially confined graded response to external 
stimuli and plasmalemmal localization of PKC [67]. Protein phosphorylation could also change their 
conformation or electric charge and consequently affect their lipid affinity and binding to the plasma 
membrane. While  myristoylation of MARCKS  is essential  for its binding to actin and the plasma 
membrane, its phosphorylation by PKC may have an electrostatic effect that affects the protein affinity 
to  the  plasma  membrane  and  consequently  interferes  with  its  actin  cross-linking  and  causes  its 
displacement from the plasma membrane. This is supported by the observation that dephosphorylation 
of MARCKS causes its re-association with the plasma membrane via its stably attached myristic acid 
membrane-targeting  moiety  [68].  Phosphorylation  of  PKC  itself  via  autophosphorylation  or  by  a 
putative PKC kinase may also determine its localization and full activation, and PKC phosphorylation 
sites have been identified in the catalytic domain of -, - and -PKC [69]. Also, binding sites for 
arginine-rich polypeptides have been identified in the PKC molecule distal to its catalytic site allowing 
targeting of PKC to target substrates at specific subcellular locations [70]. Receptors for activated  
C-kinase (RACKs) may target PKC to cytoskeletal elements, while a peptide inhibitor derived from 
the PKC binding proteins annexin I and RACKI may interfere with translocation of -PKC [71]. 
6. PKC Function 
PKC is involved in many physiological functions including secretion and exocytosis, modulation of 
ion channel, gene expression and cell growth and proliferation [21,49]. For example, transfection of a 
vector containing the full-length cDNA encoding I-PKC in rat fibroblasts led to overexpression of the Pharmaceuticals 2013, 6  415 
 
 
isozyme and caused cell growth abnormalities that mimicked the effects of the tumor promoter phorbol 
esters. However, these cell lines did not exhibit the typical characteristics of malignantly transformed 
fibroblasts. Hence, the overproduction of PKC per se may not be sufficient to cause cancer, although it 
may facilitate the cell conversion to malignancy by genotoxic agents [72]. 
PKC  may  exert  negative-feedback  control  over  cell  signaling  by  downregulation  of  surface 
receptors and/or inhibition of agonist-induced activation of PLC and phosphoinositide hydrolysis [21]. 
Also, PKC may play a role in VSM contraction [18,21,49,73]. PKC activators such as DAG analogs 
and phorbol esters cause contraction in isolated blood vessels ex vivo [17,18,49]. Phorbol ester-induced 
vascular contraction is not associated with detectable increases in [Ca
2+]I, and a role of Ca
2+-independent  
-PKC has been suggested [24,42]. Also, PKC inhibitors inhibit agonist-induced contraction of coronary 
VSM [17,73]. However, PKC may induce phosphorylation of MLC kinase leading to inhibition of 
VSM contraction [60]. 
PKC-induced phosphorylation of certain substrates may activate a cascade of protein kinases that 
enhance VSM contraction [74]. PKC-induced phosphorylation of CPI-17 promotes the inhibition of 
MLC  phosphatase  and  leads  to  further  increases  in  MLC  phosphorylation  and  VSM  contraction 
(Figure 1) [59]. -PKC-induced phosphorylation of the actin binding protein calponin could reverse 
the  calponin-mediated  inhibition  of  actin-activated  myosin  ATPase,  thus  allowing  more  actin  to 
interact with myosin and enhance VSM contraction (Figure 1) [18,29]. 
Mitogen-activated  protein  kinase  (MAPK)  is  a  Ser/Thr  protein  kinase  that  requires  dual 
phosphorylation  at  both  the  Thr  and  Tyr  residues  for  its  activation.  In  quiescent  undifferentiated 
VSMCs, MAPK is mainly in the cytosol, but upon cell activation by a growth factor or a mitogen, 
MAPK undergoes translocation from the cytosol to the nucleus where it promotes gene expression and 
cell  growth  [75].  Importantly,  tyrosine  kinase  and  MAPK  activities  have  been  identified  in 
differentiated contractile VSM, suggesting a role in VSM contraction [74]. Activation of differentiated 
VSMCs  with  the  -adrenergic  agonist  phenylephrine  is  associated  with  an  initial  translocation  of 
MAPK  from  the  cytosol  to  the  surface  membrane.  However,  during  maintained  VSM  activation 
MAPK undergoes redistribution from the surface membrane to the cytoskeleton [74]. It is likely that 
agonist-induced activation and generation of DAG at the surface membrane promotes translocation of 
the  Ca
2+-independent  ε-PKC  from  the  cytosol  to  the  surface  membrane,  where  it  becomes  fully 
activated. Activated ε-PKC in turn promotes translocation of both MAPK kinase (MEK) and MAPK 
from  the  cytosol  to  the  surface  membrane  to  form  a  protein  kinase  complex.  PKC  then  induces 
phosphorylation and activation of MEK, which in turn causes phosphorylation of MAPK at both Thr 
and  Tyr  residues  [76].  Tyr-phosphorylated  MAPK  is  then  targeted  to  the  cytoskeleton,  where  it 
induces  phosphorylation  of  the  actin-binding  protein  caldesmon  [77,78].  The  phosphorylation  of 
caldesmon reverses its inhibition of actin-mediated MgATPase activity leading to further increases in 
actin-myosin crossbridge cycling and VSM contraction (Figure 1) [18,74]. 
7. PKC Activators 
PKC isoforms have different sensitivity to Ca
2+, phosphatidylserine, DAG and other phospholipid 
products. Ca
2+-dependent PKCs bind Ca
2+ in a phospholipid-dependent manner such that Ca
2+ may 
form a “bridge” holding the PKC-phospholipid complex at the plasma membrane [79]. Phosphatidylserine Pharmaceuticals 2013, 6  416 
 
 
is required for activation of most PKCs. Phosphatidylinositol and phosphatidic acid may activate PKC, 
but may require high Ca
2+ concentrations. DAG activates Ca
2+-independent PKCs and reduces the Ca
2+ 
requirement for activation and membrane association
 of Ca
2+-dependent PKCs [21]. 
Lipids derived from sources other than glycerolipid hydrolysis such as cis-unsaturated free fatty 
acids and lysophosphatidylcholine, ceramide (a sphingomyelinase product), phosphatidylinositol 
3,4,5-trisphosphate and cholesterol sulfate may also activate PKC [80]. Other PKC activators include 
phorbol esters such as 12-o-tetradecanoylphorbol-13-acetate (TPA), phorbol myristate acetate (PMA) 
and phorbol 12,13-dibutyrate (PDBu). Phorbol esters reduce the apparent Km of PKC for Ca
2+ and 
stabilize it in the membrane-bound form [49]. 
Bryostatin, a marine natural product, binds to and activates PKC and is more potent than PMA in 
translocating - and -PKC but is not a carcinogen or a complete tumor promoter [81]. Oxidized low 
density lipoprotein (LDL) increases the activity of - and -PKC in coronary VSM, and promotes 
coronary artery vasoconstriction and atherogenesis [82]. -Radiation may activate - and -PKC, and 
in turn promote smooth muscle cell apoptosis [83]. 
PKC activity and affinity for its substrate could be modified by its phosphorylation by other protein 
kinases or even by its own autophosphorylation [84–86]. -, I- and II-PKC are expressed as inactive 
precursors that require phosphorylation by a “PKC kinase” for permissive activation. Phosphorylation 
of -PKC may prevent its down-regulation during prolonged exposure to phorbol ester [85]. Also, 
phosphorylation of II-PKC at the C-terminus allows it to bind ATP and substrate with higher affinity. 
Phosphorylation of structure determinants in the regulatory domain of PKC may increase its affinity to 
Ca
2+ [86]. Autophosphorylation of the Ca
2+-independent -PKC at Ser-643 may occur in vivo, and 
consequently control the activity and biological function of -PKC [84]. 
8. PKC Inhibitors 
Several PKC inhibitors with different affinity, efficacy and specificity have been developed (Table 2). 
PKC inhibitors acting on the catalytic domain by competing with ATP are not specific and inhibit 
other  protein  kinases.  PKC  inhibitors  acting  on  the  regulatory  domain  by  competing  at  the 
DAG/phorbol ester or the phosphatidylserine  binding site  may  be  more specific.  While prolonged 
exposure to phorbol esters can downregulate -, -, -, and -PKC [38], the tumor promoting actions 
of phorbol esters limit their use. 
The pseudosubstrate region in the regulatory domain of PKC contains an amino acid sequence between 
the  19  and  36  residues  that  resembles  the  substrate  phosphorylation  site.  Synthetic  pseudosubstrate 
inhibitor  peptides  (19  to  36)  inhibit  specific  PKCs  by  exploiting  their  substrate  specificity  without 
interfering with ATP binding. These synthetic peptides inhibits both PKC substrate phosphorylation and 
PKC autophosphorylation [47]. Also, myr-PKC, a myristoylated peptide based on the substrate motif of 
- and -PKC, inhibits TPA-induced PKC activation and phosphorylation of MARCKS [87]. 
In smooth muscle, -tocopherol inhibits the expression, activity and phosphorylation of -PKC, 
while -tocopherol protects PKC from the inhibitory effects of -tocopherol [88]. 
Short interference RNA (siRNA) can prevent the expression of a specific PKC isoform and thereby 
determine its role in a specific cellular function. Antisense techniques, knockout mice and transgenic 
animals have also been used to study the effects of downregulation of a specific PKC isoform in vivo. Pharmaceuticals 2013, 6  417 
 
 
Table 2. Representative PKC Inhibitors. 
Chemical Group  Example  Site of Action  Specificity 
1-(5-isoquinolinesulfonyl)-2-
methylpiperazines 
H-7 
Catalytic 
domain 
Compete with 
ATP at the ATP 
binding site 
Also, inhibits cyclic AMP 
and cyclic GMP-dependent 
protein kinases 
Microbial Alkaloids, 
Products of Streptomyces 
Staurosporine 
SCH47112 
Catalytic 
domain, 
ATP binding 
site 
Also, inhibits MLC kinase 
and tyrosine kinase 
Benzophenanthridine 
Alkaloids 
Chelerythrine 
Catalytic 
domain 
Competitive inhibitor with 
histone IIIS 
Indocarbazoles  Gö 6976 
Catalytic 
domain 
Ca
2+-dependent - and I-
PKC 
Bisindolylmaleimide 
Staurosporine Analogs 
GF109203X 
Ro-318220 
Midostaurin (PKC412, 
CGP41251) 
Ruboxistaurin 
(LY333531) 
Catalytic 
domain 
PKC isozymes , I, II, 
,  and . 
Ruboxistaurin mesylate 
is a selective antagonist of 
PKC βI and PKC βII. 
Perylenequinone Metabolites 
from Cladosporium 
cladosporioides 
Calphostin C 
(UCN-1028A) 
Regulatory 
domain 
Binds to the regulatory 
domain at DAG/phorbol 
ester binding site 
Membrane lipids  Sphingosine 
Regulatory 
domain 
Competitive inhibitor with 
phosphatidylserine 
Other: 
Adriamycin 
Aminoacridine 
Apigenin  
Cercosporin 
Chlorpromazine 
Dexniguldipine 
Polymixin B 
Sangivamycin 
Tamoxifen 
Trifluoperazine 
UCN-01, UCN-02 
   
9. PKC and Hypertension 
HTN is a multifactorial disorder that involves changes in the neural, hormonal, renal and vascular 
control mechanisms of BP [89]. Increases in the amount and activity of PKC could cause disturbance 
in one or more of these physiological control mechanisms, leading to persistent increases in BP and 
HTN. PKC could promote VSM growth, proliferation and contraction pathways. The relation between 
PKC and HTN could also involve changes in the vascular endothelium, ECM and MMPs-mediated 
vascular  remodeling,  oxidative  stress  and  free  radicals,  renal  hemodynamics  and  renin-angioensin Pharmaceuticals 2013, 6  418 
 
 
system,  neuronal  changes  and  sympathetic  hyperactivity,  vascular  inflammation  and  potential 
interactions with inflammatory cytokines, and other metabolic factors (Figure 3). 
Figure 3. Role of PKC in hypertension. Genetic, dietary and environmental risk factors, 
lead to vascular, neural and renal dysfunction, and increased release of various mediators 
from endothelial cells (ROS, ET-1, ANG II), sympathetic neurons (norepinephrine) and the 
kidney (ANG II). These mediators could stimulate VSM and activate PKC, as well as Ca
2+, 
Rho  kinase,  and  MAPK  thereby  induce  vasoconstriction  and  VSM  growth  and 
proliferation.  The  interaction  of  PKC  with  matrix  metalloproteinases  (MMPs)  in  the 
extracellular  matrix  (ECM)  could  contribute  to  vascular  remodeling.  Activation  of  the 
renin-angiotensin system (RAS) and increased ANG II production induce salt and water 
retention and increase plasma volume. Persistent increases in peripheral vascular resistance 
and plasma volume lead to hypertension. 
 
10. PKC and VSM Growth and Reactivity in Hypertension 
Increased expression/activity of PKC could promote trophic changes in VSM and lead to increases 
in the vessel wall thickness and hypertrophic remodeling  (Figure 3). Overexpression of  -PKC  in 
A7r5 VSMC line stimulates cell proliferation [90]. Also, the localization of -PKC in the vicinity of 
the nucleus suggests a role in VSM growth and the hypertrophic remodeling associated with HTN [41,42]. 
Combined increases in PKC activity and [Ca
2+]i could exert trophic effects in both the vasculature and 
the heart, leading to narrowing of the arterial lumen and cardiac hypertrophy in long-standing HTN [57]. 
Increased  PKC  expression  and  activity  could  also  enhance  vasoconstriction  and  increase  vascular 
resistance and BP (Figure 3). -PKC activation has been shown to enhance VSM contraction, and its Pharmaceuticals 2013, 6  419 
 
 
overexpression  in  VSM  may  be  involved  in  HTN  [41,42].  Also,  the  Ca
2+-independent  -PKC  may 
enhance  the  myofilament  force  sensitivity  to  [Ca
2+]i  in  VSM  and  promote  the  vasoconstriction 
associated with HTN [18,42]. The localization of -PKC in the cytoskeleton suggests that it may play a 
role in the vascular remodeling observed in HTN [49]. 
11. PKC in Genetic Hypertension 
Genetic linkage studies in certain families have supported the genetic origin of HTN. For instance, 
mutations  in  BMPR2  gene,  which  encodes  a  bone  morphogenetic  protein  receptor  II,  a  TGF- 
superfamily  member, have been  linked to 55% of  familial pulmonary  arterial HTN [91–93]. Mice 
carrying BMPR2 heterozygous alleles (BMPR2
+/−) are genetically equivalent to mutant human gene 
and develop pulmonary arterial HTN under stress conditions [94]. Proteomics studies on mouse tissues 
have identified -PKC as one of the signaling pathways associated with BMPR2 [95], suggesting a 
role of PKC in genetic HTN. 
PKC  may  also  play  a  role  in  spontaneously  hypertensive  rats  (SHR).  Norepinephrine-induced 
contraction is more readily inhibited by the PKC inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine 
(H-7) in the aorta of SHR than Wistar-Kyoto rats (WKY). Also, treatment of the aortic segments with 
H-7 causes a shift to the right in the concentration-contraction curve of the PKC activator TPA in the 
aorta of SHR, but not WKY [96]. The PKC activator PDBu also produces contraction and greater 
reduction  in  cytosolic  PKC  in  the  aorta  of  SHR  than  WKY  [97].  In  SHR,  -interferon  restores  
PKC  level to that in  normal control rat, suggesting an  interaction  between PKC and cytokines  in  
genetic HTN [98]. 
The role of PKC in genetic HTN has been further studied by measuring vascular contraction and 
PKC  activity  during  the  development  of  HTN  in  young  (5–6  weeks)  SHR.  High  KCl-induced 
contraction in intact mesenteric arteries and the Ca
2+-force relationship in vessels permeabilized with 
-toxin were not different in SHR and WKY rats. Treatment with the PKC activator PDBu caused 
greater enhancement of high KCl-induced contraction in intact vessels and the Ca
2+-force relationship 
in permeabilized vessels of SHR than those of WKY. The PKC inhibitors H-7 and calphostin C caused 
greater inhibition of contraction in blood vessels of SHR than WKY. These data support that PKC 
enhances the Ca
2+ sensitivity of the contractile proteins in VSM to a greater extent in blood vessels of 
young prehypertensive SHR than WKY. The data also suggest that PKC activation in VSM occurs 
before overt HTN, and support a causative role of PKC in the development of genetic HTN [99]. 
To further examine potential inborn differences in vascular PKC before the onset of HTN, studies 
have compared VSM proliferation in cells from young (1–2 week) SHR and WKY rats. In cultured 
aortic VSM from SHR and WKY rats, both ANG II and endothelin-1 (ET-1) enhanced thymidine 
incorporation into DNA, an indicator of DNA synthesis. Treatment of VSMCs with the PKC inhibitor 
chelerythrine  caused  greater  suppression  of  ANG  II  and  ET-1  induced  DNA  synthesis  and  VSM 
growth in cells of SHR than WKY, suggesting an inborn increase in PKC activity in VSMCs of SHR [100]. 
In a study assessing the role of PKC in the changes in vascular tone associated with genetic HTN  
in vivo, it was found that perfusing the PKC activator PDBu in the hindlimb of anesthetized SHR and 
WKY rats caused prolonged vasoconstriction and increased perfusion pressure. The PDBu-induced 
vasoconstriction and increased perfusion pressure were inhibited by the PKC inhibitor staurosporine to Pharmaceuticals 2013, 6  420 
 
 
a greater extent in SHR than WKY rats, supporting a role of PKC in the regulation of vascular function 
and BP in vivo, and increased PKC expression and activity in VSM of rat models of genetic HTN [101]. 
Sex differences in the expression and activity of PKC have been observed in VSM of WKY and 
SHR. VSM contraction and the expression and activity of -, - and -PKC in response to the phorbol 
ester PDBu are less in intact female than intact male WKY, and these sex differences are greater in 
VSM from SHR than WKY rats [102]. PDBu-induced contraction and PKC activity were similar in 
castrated  and  intact  male  rats,  but  greater  in  ovariectomized  (OVX)  than  in  intact  female  rats. 
Treatment  of  OVX  females  with  17-estradiol  subcutaneous  implants  caused  reduction  in  PDBu 
contraction  and  PKC  activity,  that  were  greater  in  SHR  than  WKY  rats.  These  data  suggested  
sex-related reduction  in VSM contraction and the expression and activity of  -, - and -PKC  in 
female compared with male rats, and that these differences are likely mediated by estrogen and are 
enhanced in genetic HTN [102]. 
12. PKC and Human Essential Hypertension 
Studies have shown an increase in oxidative stress and growth response in VSMCs from resistance 
arteries of patients with essential HTN as compared to cells  from  normotensive controls. ANG  II 
increases ROS to a greater extent in VSM from hypertensive than normotensive subjects. Also, ANG II 
increases  phospholipase  D  (PLD)  activity  and  DNA  and  protein  synthesis  to  a  greater  extent  in 
VSMCs from hypertensive than normotensive subjects, and the ANG II effects are partially inhibited 
by treating the cells with the PKC inhibitors chelerythrine and calphostin C. These data suggest that 
the increased oxidative stress and growth-promoting effects of ANG II in VSMCs from hypertensive 
patients may involve increased activity of PLD- and PKC-dependent pathways and further support a 
role of these pathways in the vascular remodeling associated with HTN [103]. 
One of the properties of PKC is that it undergoes translocation from the cytosol to cell membrane 
during  VSM  activation,  a  property  that  can  be  used  in  the  diagnosis  and  prognosis  of  VSM 
hyperactivity in HTN. However, the subcellular distribution of PKC may vary depending on the type 
and  abundance  of  membrane  lipids.  Studies  have  shown  increased  cholesterol/phospholipid  ratio, 
higher  levels  of  monounsaturated  fatty  acids,  and  lower  levels  of  polyunsaturated  fatty  acids  in 
erythrocyte membranes from elderly hypertensive subjects as compared to normotensive controls. On 
the  other  hand,  the  levels  of  activated  membrane-associated  PKC  are  not  increased,  but  rather 
decreased  in  erythrocytes  of  elderly  hypertensive  subjects,  which  may  not  be  related  to  the 
etiopathology of HTN, but represent an adaptive compensatory mechanism to HTN [104]. 
13. PKC and Aortic Constriction-Induced Hypertension 
PKC  activation  and  translocation  are  increased  in  a  rat  model  of  pressure  overload  and  left 
ventricular hypertrophy produced by banding or clipping of the aorta [41]. The increased PKC activity 
is associated with increased tritiated phorbol ester ([
3H]PDBu) binding and PKC concentration in both 
the cytosolic and membrane fractions [105]. Immunoblot analysis has revealed that the increased PKC 
activity is mainly due to increases in the amount of I-, II- and -PKC in the surface membrane and 
nuclear-cytoskeletal fractions [105]. Imaging of the subcellular distribution of PKC revealed that in 
VSMCs of normotensive rats -PKC is mainly in the cytosol, while -PKC is in the perinuclear area [40,42]. Pharmaceuticals 2013, 6  421 
 
 
In VSMCs of hypertensive rats, -PKC is activated and localized at the surface membrane, while -PKC is 
localized in the nucleus [41]. 
14. PKC, Endothelial Dysfunction and Hypertension 
Changes in PKC activity in the endothelium could contribute to the regulation of vascular function 
and BP. Studies have suggested a role of PKC in the endothelial cell dysfunction observed in blood 
vessels of SHR and deoxycorticosterone acetate (DOCA)-salt hypertensive rats [106,107]. NO is one 
of the major vasodilators produced by the endothelium. Activated endothelial NO synthase (eNOS) 
catalyzes the transformation of L-arginine to L-citrulline and the production of NO. Mice deficient in 
eNOS are hypertensive and lack NO-mediated vasodilation [108]. PKC activation may affect NOS 
activity  and  NO  production  or  bioactivity.  PKC  may  cause  phosphorylation  of  Thr-495  and 
dephosphorylation of Ser-1175 in eNOS and in turn inhibit NO production [109,110]. Specifically,  
- and -PKC phosphorylate eNOS at Ser-1175 and increase NO production [111,112]. PKC may also 
play a role in eNOS “uncoupling”, a process in which eNOS is over-expressed or hyperactivated in an 
attempt to produce more NO to reduce vascular tone, but instead produces superoxide (O2
−•) [113,114]. In 
SHR, oral administration of the PKC inhibitor midostaurin, a staurosporine analog, reverses aortic 
eNOS “uncoupling”, and causes up-regulation of eNOS expression and diminished production of ROS. 
Also, aortic levels of (6R)-5,6,7,8-tetrahydro-L-biopterin (BH4), a NOS cofactor, are reduced in SHR 
compared with WKY. In addition, midostaurin lowered BP in SHR and, to a lesser extent in WKY [115], 
supporting potential benefits of PKC inhibitors in genetic HTN. 
15. PKC, Oxidative Stress and Hypertension 
Oxidative stress has been demonstrated in most forms of HTN including essential and renovascular 
HTN. Increased O2
−• production decreases NO bioactivity, and in turn increases vasoconstriction and 
vascular resistance in HTN [1–3]. The HTN-associated increase in O2
−• production in HTN may partly 
involve PKC. In isolated arteries, high pressure induces O2
−• production via PKC-dependent activation 
of  NADPH  oxidase  [3].  Also,  O2
−•  production  is  increased  in  sympathetic  neurons  of  DOCA-salt 
hypertensive rats via activation of NADPH oxidase [116]. Studies have also shown that the impaired 
vasodilation  and  increased  vascular  O2
−•  production  in  the  2  kidney-1  clip  (2K-1C)  rat  model  
of  renovascular  HTN  are  likely  related  to  PKC-mediated  activation  of  membrane-associated  
NADPH-dependent oxidase [2,3,117]. 
16. PKC, MMPs and Vascular Remodeling in Hypertension 
PKC may play a signaling role in the expression and activity of MMPs and consequently affects 
ECM composition and vascular remodeling. MMPs are a family of zinc-containing proteases that play 
a  role  in  the  degradation  of  ECM  proteins  [118–120],  and  may  have  additional  effects  on  the 
endothelium and VSM [121,122]. MMPs activity is regulated at the transcription level as well as by 
activation of their pro-form, interaction with specific ECM components, and inhibition by endogenous 
tissue inhibitors of MMPs (TIMPs). Changes in hemodynamics, vessel injury, inflammatory cytokines 
and ROS could upregulate MMPs and promote vascular remodeling and HTN. Some studies have Pharmaceuticals 2013, 6  422 
 
 
shown that the plasma levels and activity of MMP-2, MMP-9 and TIMP-1 are elevated in hypertensive 
patients [123]. Other studies have shown that the plasma levels of active MMP-2 and -9 are decreased 
in patients with essential HTN, and treatment with amlodipine normalized MMP-9 plasma levels [124]. 
These  findings  suggested  a  relationship  between  abnormal  ECM  metabolism  and  HTN,  and  that 
antihypertensive treatment may modulate collagen metabolism. In a study examining the serum levels 
of carboxy-terminal telopeptide of collagen type I (CITP) as a marker of extracellular collagen type I 
degradation, MMP-1 (collagenase), TIMP-1, and MMP-1–TIMP-1 complex, baseline free MMP-1 was 
decreased  and  baseline  free  TIMP-1  was  increased  in  hypertensive  compared  with  normotensive 
subjects.  Hypertensive  patients  treated  with  the  angiotensin-converting  enzyme  (ACE)  inhibitor 
lisinopril for 1 year showed an increase in free MMP-1, a decrease in free TIMP-1, and an increase in 
serum  CITP.  These  findings  suggest  that  systemic  extracellular  degradation  of  collagen  type  I  is 
depressed in patients with essential HTN and may facilitate organ fibrosis, and this can be normalized 
by treatment with lisinopril [7]. Also, gelatin zymographic analysis of in internal mammary artery 
from normotensive and hypertensive patients undergoing coronary artery bypass surgery, indicated a 
decrease in activity of MMP-2 and -9 in HTN. MMP-1 activity was also decreased by 4-fold without a 
change in protein levels. Immunoblot analysis revealed a decrease in the tissue levels of extracellular 
matrix metalloproteinase inducer (EMMPRIN), MMP activator protein (MT1-MMP) and MMP-9 in 
HTN. Also, measurement of plasma markers of collagen synthesis (procollagen type I amino-terminal 
propeptide [PINP]) and collagen degradation (carboxy-terminal telopeptide of collagen type I [ICTP]) 
has shown  no changes  in PINP  levels  but decreased degradation of  collagen  in HTN. These data 
demonstrate that MMP-1 and -9, MMP inducer and activator proteins are downregulated in HTN, and 
may result in increased collagen deposition in HTN [8]. 
Studies have shown that the total wall thickness and the medial area are increased in the aorta but 
not vena cava of DOCA-salt versus sham rats. In HTN, MMP-2 expression and activity were increased 
in  the  aorta  but  not  vena  cava,  while  MMP-9  was  weakly  expressed  in  both  vessels.  TIMP-2 
expression was increased in the aorta of DOCA-salt rats compared to sham, but barely detectable in 
vena cava of DOCA-salt and sham or rats. These data suggest a link between MMPs and vascular 
remodeling in the aorta of DOCA-salt hypertensive rats. The increase in TIMP-2 expression in the 
aorta of DOCA-salt rats may be an adaptive mechanism to the high levels of MMP-2 [9]. Other studies 
have shown that in wild-type mice treated with ANG II and a 5% NaCl diet for 10 days, the onset of 
HTN is accompanied by increased MMP-9 activity in conductance vessels. In contrast, in MMP-9
(−/−) 
mice, the absence of MMP-9 activity is associated with vessel stiffness and increased pulse pressure, 
suggesting  that  in  early  stages  of  HTN,  MMP-9  activation  may  preserve  vessel  compliance  and 
alleviate BP increase [125]. 
Growth factors and cytokines such as nuclear factor B and IL-1 stimulate VSMCs to secrete 
MMP-1, -3, -9, and these effects may be dependent on activation of -PKC, and may contribute to 
inhibition of VSMC proliferation and vascular remodeling [10]. PKC also increases MMP-2 secretion 
in endothelial cells [126], and PKC- plays a critical role in MMP-9 secretion in bovine capillary 
endothelial cells through ERK1/2 signaling [11]. PKC- plays a signaling role in the expression and 
activity of MMP-1 and -3 in human coronary artery endothelial cells [127]. In cardiac microvascular 
endothelial cells, IL-1 activates -PKC and I-PKC and  increases the expression and activity  of 
MMP-2, and inhibition of -PKC and I-PKC abrogates the IL-1 stimulated increase in MMP-2 [12]. Pharmaceuticals 2013, 6  423 
 
 
17. PKC in Salt-Sensitive Hypertension 
Increased dietary sodium intake causes HTN in salt-sensitive individuals [128,129]. Studies have 
shown an increase in BP and the heart to body weight ratio in DOCA salt-sensitive hypertensive rats 
compared to control rats. Also, -, - and -PKC are upregulated while -PKC is not altered in cardiac 
extracts of DOCA-salt rats compared to controls. On the other hand, -PKC is increased in cardiac 
fibroblasts from DOCA-salt rats compared to controls. These data suggest cell-specific increase in the 
expression of , ,  or -PKC in the hearts of DOCA-salt hypertensive rats [130]. Also, the PKC 
inhibitor  GF109203X  (2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)maleimide) 
decreases  both  basal  tone  and  MAPK  (ERK1/2)  activity  in  DOCA-salt  rats,  suggesting  that  the 
increased basal vascular tone and MAPK activity in DOCA-salt hypertensive rats may involve PKC [131]. 
Changes  in  cardiac  PKC  have  also  been  observed  in  Dahl  salt-sensitive  hypertensive  rats. 
Marinobufagenin, an endogenous ligand of the 1 subunit of the cardiac Na/K-ATPase, is increased in 
sodium-loaded  Dahl-salt-sensitive  rats,  and  PKC-induced  phosphorylation  of the  1  Na/K-ATPase 
may  increase  its sensitivity to marinobufagenin, and  further contribute to the increased BP  in this  
rat model [117]. 
PKC may also affect the renin-angiotensin-aldosterone system and the renal control mechanism of 
BP. Infusion of ANG II in rats causes HTN, vascular endothelial dysfunction and increased vascular 
O2
−• production. Some of the vascular effects of ANG II may be mediated by increased endothelial 
cell release of ET-1, which  in turn activates PKC [132–134]. Interestingly,  ANG II-induced ET-1 
production and PKC activity are greater in blood vessels of SHR than normotensive control rats [135]. 
Other studies have shown that cytosolic PKC activity is higher in aortic VSM from SHR than those 
from WKY or SHR treated with the angiotensin-converting enzyme (ACE) inhibitor enalapril, and the 
changes in vascular PKC activity were paralleled by changes in BP. Membrane-bound PKC activity 
was detected in aortic VSM of SHR, but not in that of the WKY or enalapril-treated SHR. Also, -PKC 
mRNA expression and protein amount were greater in aortic VSM from SHR than those from WKY or 
enalapril-treated SHR, suggesting that the beneficial effects of ACE inhibitors in HTN may in part 
involve changes in expression and activity of -PKC in VSM [136]. Other studies have shown that 
PKC could affect the Na
+/Ca
2+ exchange mechanism in the renal arterioles leading to defective renal 
vasodilation and salt-sensitive HTN [137]. 
PKC may also affect the renal tubular cells and the kidney function. In renal tubular epithelial cells, 
- and -PKC are localized in the plasma membrane whereas - and -PKC are cytosolic. Dopamine, 
an intrarenal modulator of sodium metabolism and BP, causes translocation of - and -PKC to the 
plasma  membrane  [138,139],  supporting  a  role  of  PKC  in  the  control  of  renal  sodium  and  water 
reabsorption and BP [140]. 
18. PKC, Neuronal Dysfunction and Hypertension 
PKC may play a role in the neural control mechanisms of BP. The expression and redistribution of 
PKC isozymes are increased in brain tissue of SHR [141]. Also, sympathetic nerves are known to 
control VSM contraction  by releasing chemical  transmitters such as norepinephrine, which  in turn 
trigger the increase in [Ca
2+]i and PKC activity. Polymorphisms in human tyrosine hydroxylase gene Pharmaceuticals 2013, 6  424 
 
 
have been associated with increased sympathetic activity, norepinephrine release and HTN [142], and 
the role of PKC in these hypertensive subjects remains to be investigated. 
19. PKC, Metabolic Dysfunction and Hypertension 
Metabolic  disorders  are  often  associated  with  hyperglycemia  and  glucose  intolerance,  insulin 
resistance, central and overall obesity, dyslipidemia (increased triglyceride and decreased high-density 
lipoprotein  (HDL)  cholesterol  levels),  and  different  vascular  manifestations  and  complications 
including HTN. Evidence suggests a role of PKC in these metabolic disorders. For example, glucose-induced 
increase in endothelial cell permeability is associated with activation of -PKC [143]. Also, glucose, 
via activation of PKC, may affect the Na
+/H
+ exchanger mRNA expression and activity in VSMCs [144]. 
Importantly, an antisense complementary to the mRNA initiation codon regions for  - and -PKC 
causes  downregulation  of  these  PKC  isoforms  and  inhibits  insulin-induced  glucose  uptake  in  rat 
adipocytes  [145].  Also,  inhibitors  of  -PKC  ameliorate  the  vascular  dysfunction  in  rat  models  of 
diabetes and attenuate the progression of experimental diabetic nephropathy and HTN [146]. 
20. PKC, Vascular Inflammation and Hypertension 
Vascular inflammation may play a role in cardiovascular disease [4,147]. Plasma levels of tumor 
necrosis factor- (TNF-), interleukin-1 (IL-1), and IL-6 are increased in patients with HTN and 
coronary  artery  disease  [5,6,148–151].  Also,  infusion  of  ANG  II  does  not  induce  HTN  in  IL-6 
knockout mice, supporting a role of IL-6 in HTN [152]. In isolated pulmonary artery, hypoxia causes 
upregulation  of  TNF-  and  IL-1,  a  process  that  is  dependent  on  PKC  activation  and  promotes 
pulmonary  vasoconstriction  [13].  Also, TNF-  activates  PKC  and  mitogenic  signaling  in  cultured 
VSMCs [14], and inhibition of PKC- blocks high glucose-induced secretion of TNF- in cultured rat 
and human aortic VSMCs [15]. 
21. PKC and Pulmonary Hypertension 
PKC exert specific effects on the pulmonary vessels and may play a role in pulmonary HTN. Both 
insulin-like growth factor I and PKC activation stimulate proliferation of pulmonary artery VSMCs. 
PKC  is also one of the signaling pathways  involved  in  hypoxia-induced pulmonary artery VSMC 
proliferation, and chronic hypoxia may increase PKC activity and promote growth in pulmonary artery 
adventitial  fibroblasts  [153].  Mice  deficient  in  -PKC  show  decreased  hypoxic  pulmonary 
vasoconstriction  [154].  Also, ET-1  is  a  potent  pulmonary  vasoconstrictor,  and  endothelin  receptor 
antagonists have shown benefits in patients with pulmonary HTN [155,156]. ET-1 induced pulmonary 
vasoconstriction is partly mediated by PKC, and PKC inhibitors decrease ET-1 induced pulmonary 
artery contraction [157].  
22. PKC and Hypertension-in-Pregnancy and Preeclampsia 
Normal  pregnancy  is  often  associated  with  decreased  BP,  increased  uterine  blood  flow  and 
decreased vascular responses to vasoconstrictors [158,159]. Uterine artery from pregnant sheep and 
aorta of late pregnant rats show decreased vascular contraction and PKC activity [160,161]. Also, the Pharmaceuticals 2013, 6  425 
 
 
expression, activation and translocation of the Ca
2+-dependent -PKC and the Ca
2+-independent - and 
-PKC are reduced in the aorta of late pregnant compared with nonpregnant rats [161,162]. 
In 5% to 7% of pregnancies, women develop a condition called preeclampsia characterized by 
proteinuria and severe increases in BP [159]. Studies in animal models of HTN in pregnancy have 
provided  useful  information  regarding  the  potential  causes  of  preeclampsia.  BP  is  greater  in  late 
pregnant rats treated with the NO synthase inhibitor  L-NAME, compared with normal pregnant or 
virgin  rats  nontreated  or  treated  with  L-NAME  [163].  Also,  phenylephrine-induced  contraction  is 
greater  in  aortas  from  L-NAME-treated  pregnant  rats  compared  with  normal  pregnant  or  virgin  
rats  [163,164].  Additionally,  expression  and  activity  of  vascular  -  and  -PKC  are  enhanced  in  
L-NAME-treated compared with non-treated pregnant rats [161,162], suggesting a role of - and -PKC in 
the increased vasoconstriction and vascular resistance during HTN in pregnancy [161,162]. 
PKC  may  also  play  a  role  in  the  changes  in  ANG  II  receptor-mediated  signaling  during 
preeclampsia.  In  cultured  neonatal  rat  cardiomyocytes,  immunoglobulin  from  preeclamptic  women 
enhances angiotensin type 1 (AT1) receptor-mediated chronotropic response, while immunoglobulin 
from control subjects has no effect, and the chronotropic effects of imunoglobulin are prevented by the 
PKC  inhibitor  calphostin  C.  Also,  confocal  microscopy  of  VSMCs  has  shown  colocalization  of 
purified IgG from preeclamptic women and AT1 receptor antibody. These findings have suggested that 
preeclamptic women develop auto-antibodies that stimulate AT1 receptor, a process that may to be 
mediated by PKC [165]. 
Experimental studies have suggested that reduction in uteroplacental perfusion pressure and the 
ensuing placental ischemia or hypoxia during late pregnancy may increase the release of cytokines into 
the maternal circulation, which in turn cause generalized vascular changes and HTN [159,166–170]. 
Plasma levels of TNF- are elevated in women with preeclampsia [168,169]. Sources other than the 
placenta may also contribute to the elevated serum levels of TNF- in preeclamptic women [171]. 
Interestingly,  infusion  of  TNF-  or  IL-6  in  pregnant  rats  to  reach  plasma  levels  similar  to  those 
observed in preeclampsia, are associated with inceassed BP and systemic vasoconstriction [172,173]. 
Also, treatment of  aortic  segments  from  pregnant  rats  with  TNF-  or IL-6  enhances  reactivity  to 
vasoconstrictor stimuli [174,175]. Cytokines may increase the expression and activity of vascular PKC 
leading to increased myofilament force sensitivity to [Ca
2+]i and enhanced VSM contraction. Other 
vasoactive factors such as soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng) may 
be released during reduction of uteroplacental perfusion pressure [176,177] and their effects on PKC 
need to be examined. 
23. PKC Inhibitors as Modulators of Vascular Function in Hypertension 
The effects of PKC inhibitors on VSM contraction has been examined in isolated blood vessels, but 
the in vivo effects of PKC inhibitors have not been fully examined. Dahl-salt-sensitive rats on high 
NaCl (8%) diet exhibit an increase in BP, excretion of the endogenous inhibitor of 1 Na/K-ATPase 
marinobufagenin,  left  ventricular  weight,  and  myocardial  Na/K-ATPase  and  II-PKC  and  -PKC. 
Treatment  of  Dahl-salt  rats  with  cicletanine  causes  reduction  in  BP  and  left  ventricular  weight, 
decreased  sensitivity  of  Na/K-ATPase  to  marinobufagenin,  no  increase  in  II-PKC,  and  reduced 
phorbol  diacetate-induced  Na/K-ATPase  phosphorylation.  The  cicletanine-induced  decrease  in  BP Pharmaceuticals 2013, 6  426 
 
 
may  be  due  to  targeting  of  PKC-induced  phosphorylation  of  cardiac  1  Na/K-ATPase  [117].  
In isolated human mesenteric artery, marinobufagenin induces sustained vasoconstriction, possibly due 
to inhibition of the plasmalemmal Na/K-ATPase activity. Treatment of the vessel with cicletanine 
inhibited  marinobufagenin-induced  contraction  and  attenuated  marinobufagenin-induced  Na/K-ATPase 
inhibition,  and  the  effects  of  cicletanine  were  prevented  by  the  PKC  activator  phorbol  diacetate. 
Similarly,  in  rat  brain  cicletanine  inhibits  PKC  activity,  and  these  inhibitory  effects  on  PKC  are 
prevented  in  the  presence  of  phorbol  diacetate.  These  data  suggest  that  PKC  is  involved  in  the 
regulation of Na/K-ATPase and vascular tone, and may represent a potential target for therapeutic 
intervention in HTN [178]. 
It is important to note that HTN is a multifactorial disease, and PKC inhibitors alone may not be 
sufficient to manage HTN. However, PKC inhibitors may decrease the VSM growth and hyperactivity 
associated with HTN particularly when used with other therapeutic modalities. PKC inhibitors could 
potentiate the inhibitory effects of Ca
2+ channel blockers on vasoconstriction. Targeting Ca
2+-independent 
PKCs could be beneficial in Ca
2+ antagonist-resistant forms of HTN. The effects of PKC inhibitors in 
reducing  vasoconstriction  and  BP  could  also  be  potentiated  by  Rho-kinase  and  MAPK  inhibitors. 
RhoA/Rho-kinase  causes  inhibition  of  MLC  phosphatase  and  thereby  enhances  Ca
2+-MLC  kinase 
dependent VSM contraction, and may play a role in the development and progression of HTN [152,179]. 
The interaction between PKC and other pathways such as ROS, MMPs and inflammatory cytokines 
could also be associated with vascular disease. The combined use of isoform-specific PKC inhibitors 
with antioxidants, MMPs inhibitors and cytokine antagonists may provide a multi-prong approach for 
treatment of Ca
2+ antagonist-insensitive forms of HTN. 
Upregulation of PKC could play a role not only in vascular disease such as HTN and atherogenesis, 
but also in metabolic disorders, insulin resistance and cancer in what has been termed as the “PKC 
syndrome” [180]. Therefore, it is important to further test the effects of PKC inhibitors in vivo and in 
animal models of HTN with other co-morbidities such as hypercholesterolemia and diabetes. Although 
the first generation of PKC inhibitors may not be very selective, newly-developed PKC inhibitors are 
more specific, and further experimental studies and clinical trials are needed before these compounds 
can be used safely in human. Certain PKC inhibitors such as ruboxistaurin (LY333531), a selective -PKC 
inhibitor,  have  shown  promise  in  clinical  trials  for  diabetic  retinopathy,  macular  edema  and 
microvascular complications [181–183]. Using similar strategies to develop specific inhibitors of -, 
-  or  -PKC  isoform  with  improved  enzyme  selectivity  and  pharmakokinetics  may  lead  to  new 
therapies for HTN. 
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